Payment overview · 2025
General Payments
$140.42
6 reported records · 6 companies
Healthcare provider profile · identity verified
Kai Li, MD
Allopathic & Osteopathic Physicians|Internal Medicine · OREGON CITY, OR · NPI 1427153238
Verified facts
What the public records show
CMS Open Payments records show Kai Li, MD received $140.42 in general payments during 2025 across 6 reported records.
Amgen Inc. accounted for 20.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Farxiga by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 196 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $28.13 | 20.0% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $28.08 | 20.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $22.61 | 16.1% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $22.28 | 15.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $21.74 | 15.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.58 | 12.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $140.42 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $28.13 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $28.13 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $28.08 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $22.61 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $22.28 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $21.74 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $17.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 196 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 54 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
196 | 45 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
54 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 777 | 216 |
| Losartan Potassium | Losartan Potassium | 551 | 156 |
| Amlodipine Besylate | Amlodipine Besylate | 505 | 134 |
| Lisinopril | Lisinopril | 460 | 122 |
| Levothyroxine Sodium | Levothyroxine Sodium | 451 | 110 |
| Gabapentin | Gabapentin | 401 | 95 |
| Tamsulosin Hcl | Tamsulosin Hcl | 398 | 107 |
| Metoprolol Succinate | Metoprolol Succinate | 375 | 109 |
| Omeprazole | Omeprazole | 373 | 102 |
| Metformin Hcl | Metformin Hcl | 330 | 97 |
| Hydrochlorothiazide | Hydrochlorothiazide | 319 | 86 |
| Oxycodone Hcl | Oxycodone Hcl | 283 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 282 | 107 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 236 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 226 | 61 |
| Trazodone Hcl | Trazodone Hcl | 205 | 51 |
| Potassium Chloride | Potassium Chloride | 204 | 53 |
| Allopurinol | Allopurinol | 196 | 54 |
| Eliquis | Apixaban | 196 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 188 | 46 |
| Furosemide | Furosemide | 171 | 46 |
| Simvastatin | Simvastatin | 150 | 40 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 138 | 38 |
| Metformin Hcl Er | Metformin Hcl | 131 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 130 | 33 |
| Glipizide | Glipizide | 125 | 35 |
| Doxazosin Mesylate | Doxazosin Mesylate | 119 | 25 |
| Finasteride | Finasteride | 119 | 33 |
| Atenolol | Atenolol | 118 | 30 |
| Carvedilol | Carvedilol | 114 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 111 | 31 |
| Zolpidem Tartrate | Zolpidem Tartrate | 107 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 104 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 101 | 26 |
| Tramadol Hcl | Tramadol Hcl | 100 | 23 |
| Lovastatin | Lovastatin | 86 | 24 |
| Sertraline Hcl | Sertraline Hcl | 79 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 78 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 77 | 21 |
| Morphine Sulfate Er | Morphine Sulfate | 77 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 71 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 69 | 13 |
| Clonazepam | Clonazepam | 63 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 62 | 17 |
| Synthroid | Levothyroxine Sodium | 60 | 12 |
| Bupropion Xl | Bupropion Hcl | 59 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 59 | 12 |
| Warfarin Sodium | Warfarin Sodium | 59 | 13 |
| Hydromorphone Hcl | Hydromorphone Hcl | 57 | suppressed |
| Mirtazapine | Mirtazapine | 57 | 11 |
| Nystatin | Nystatin | 57 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 57 | 13 |
| Donepezil Hcl | Donepezil Hcl | 56 | 16 |
| Jardiance | Empagliflozin | 56 | 13 |
| Famotidine | Famotidine | 55 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 54 | 11 |
| Alendronate Sodium | Alendronate Sodium | 53 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 52 | 16 |
| Ezetimibe | Ezetimibe | 52 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 52 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 50 | 19 |
| Spironolactone | Spironolactone | 49 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 48 | 13 |
| Glipizide Er | Glipizide | 47 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 44 | 11 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 43 | suppressed |
| Acyclovir | Acyclovir | 41 | 20 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 41 | 12 |
| Ozempic | Semaglutide | 40 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 40 | 11 |
| Oxycontin | Oxycodone Hcl | 39 | suppressed |
| Lorazepam | Lorazepam | 38 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 38 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 36 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 36 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 36 | 30 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 36 | suppressed |
| Glimepiride | Glimepiride | 35 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 35 | suppressed |
| Mupirocin | Mupirocin | 34 | 16 |
| Clonidine Hcl | Clonidine Hcl | 32 | suppressed |
| Alprazolam | Alprazolam | 31 | suppressed |
| Folic Acid | Folic Acid | 31 | suppressed |
| Trulicity | Dulaglutide | 31 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 31 | suppressed |
| Memantine Hcl | Memantine Hcl | 29 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | suppressed |
| Valsartan | Valsartan | 28 | suppressed |
| Amoxicillin | Amoxicillin | 27 | 16 |
| Bupropion Hcl Sr | Bupropion Hcl | 27 | suppressed |
| Torsemide | Torsemide | 27 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 26 | suppressed |
| Azithromycin | Azithromycin | 26 | 18 |
| Pregabalin | Pregabalin | 26 | suppressed |
| Meloxicam | Meloxicam | 25 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 25 | suppressed |
| Cephalexin | Cephalexin | 24 | 20 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Dulera | Mometasone/Formoterol | 22 | suppressed |
| Naproxen | Naproxen | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 21 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 20 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | 12 |
| Nitroglycerin | Nitroglycerin | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | suppressed |
| Prednisone | Prednisone | 19 | 14 |
| Risperidone | Risperidone | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Cyclosporine | Cyclosporine | 16 | suppressed |
| Epinephrine | Epinephrine | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Armour Thyroid | Thyroid,pork | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Risperidone Odt | Risperidone | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | 11 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $140.42 · 6 records | Amgen Inc. | BREZTRI, ELIQUIS, OTEZLA, Ozempic, REPATHA, REXULTI, TRELEGY ELLIPTA | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error